Mouse Model of Cervicovaginal Papillomavirus Infection

  • Nicolas Çuburu
  • Rebecca J. Cerio
  • Cynthia D. Thompson
  • Patricia M. Day
Protocol
First Online:
Part of the Methods in Molecular Biology book series (MIMB, volume 1249)

Abstract

Virtually all cervical cancers are caused by human papillomavirus infections. The efficient assembly of pseudovirus (PsV) particles incorporating a plasmid expressing a reporter gene has been an invaluable tool in the development of in vitro neutralization assays and in studies of the early mechanisms of viral entry in vitro. Here, we describe a mouse model of human papillomavirus PsV infection of the cervicovaginal epithelium that recapitulates the early events of papillomavirus infection in vivo.

Key words

Human papillomavirus Pseudovirions Cervicovaginal mucosa Mouse model Infection 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

This work was supported by the National Cancer Institute intramural program.

References

  1. 1.
    de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13:607–615PubMedCrossRefGoogle Scholar
  2. 2.
    Buck CB, Pastrana DV, Lowy DR, Schiller JT (2004) Efficient intracellular assembly of papillomaviral vectors. J Virol 78:751–757PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Buck CB, Pastrana DV, Lowy DR, Schiller JT (2005) Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med 119:445–462PubMedGoogle Scholar
  4. 4.
    Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, Lowy DR, Schiller JT (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13:857–861PubMedCrossRefGoogle Scholar
  5. 5.
    Kines RC, Thompson CD, Lowy DR, Schiller JT, Day PM (2009) The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci U S A 106:20458–20463PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, Day PM (2009) Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol 83:2067–2074PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, Lowy DR, Schiller JT (2010) In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 8:260–270PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Cuburu N, Graham BS, Buck CB, Kines RC, Pang YY, Day PM, Lowy DR, Schiller JT (2012) Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. J Clin Invest 122:4606–4620PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Niruthisard S, Roddy RE, Chutivongse S (1991) The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Sex Transm Dis 18:176–179PubMedCrossRefGoogle Scholar
  10. 10.
    Day PM, Pang YY, Kines RC, Thompson CD, Lowy DR, Schiller JT (2012) A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin Vaccine Immunol 19:1075–1082PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Baumgarth N, Roederer M (2000) A practical approach to multicolor flow cytometry for immunophenotyping. J Immunol Methods 243:77–97PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Nicolas Çuburu
    • 1
  • Rebecca J. Cerio
    • 1
  • Cynthia D. Thompson
    • 1
  • Patricia M. Day
    • 1
  1. 1.Laboratory of Cellular Oncology, Center for Cancer ResearchNational Cancer Institute, National Institutes of HealthBethesdaUSA

Personalised recommendations